

MYLAN'S BALANCED PRICING MODEL

Given our long history of providing high quality, low cost generic pharmaceuticals, we are uniquely situated to work with customers, payors, non-governmental organizations (NGOs) and other partners to find solutions and meet the needs of the patients and families we serve. We also have a strong track record of developing new products, particularly complex and difficult-to-formulate medicines, and are committed to making safe, high-quality products accessible to patients across all income levels.

With respect to Mylan's generic portfolio, we offer hundreds of affordable products all at a fraction of the price of the equivalent brand name medicine. The prices of these drugs often decrease every year. As negotiations occur with our customers or as we participate in tender programs or public/private partnerships around the globe, we will continue to do so based on an assessment of supply, demand, patient need and the affordability of our product, especially as it relates to the equivalent brand name drug.

As it pertains to our brand portfolio, Mylan is committed to pricing its products in a way that reflects their value to patients and providers. Mylan will endeavor to not raise the prices of our branded products more than once per year, however we will assess the prices of our products on a regular basis. Our aim is for any price increases to be reasonable in light of relevant factors, including current economic indicators and the state of the overall business marketplace.

The socioeconomic conditions within each market that Mylan does business are inherently considered as part of our generic and brand pricing assessments, as is the importance of sustaining our ability to consistently provide patients in each market with the quality products needed. This is reflected in our ability to provide 59 billion doses of medicine in 2018 to more than 165 countries and territories around the world at an average price of 19 cents per dose.